| Identification | Back Directory | [Name]
LY-503,430 | [CAS]
625820-83-9 | [Synonyms]
LY-503,430
[1,1'-Biphenyl]-4-carboxamide, 4'-[(1S)-1-fluoro-1-methyl-2-[[(1-methylethyl)sulfonyl]amino]ethyl]-N-methyl- | [Molecular Formula]
C20H25FN2O3S | [MDL Number]
MFCD08690467 | [MOL File]
625820-83-9.mol | [Molecular Weight]
392.49 |
| Hazard Information | Back Directory | [Uses]
LY-503430 is an orally active AMPA receptor positive allosteric modulator (PAM). LY-503430 can be used for the study of Parkinson's disease[1]. | [in vivo]
LY503430 (0.5 mg/kg; s.c; once a day; for 11 days) has functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease[1]. | Animal Model: | Male C57Bl6J mice (20-25 g) injected with MPTP (HY-15608)[1] | | Dosage: | 0.5 mg/kg | | Administration: | s.c; once a day; for 11 days | | Result: | Prevention of MPTP-induced neurotoxicity in mice.
|
| [References]
[1] Tracey K Murray, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2003 Aug;306(2):752-62. DOI:10.1124/jpet.103.049445 |
|
|